Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients

Trial Profile

Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Apr 2018

At a glance

  • Drugs REP 2139-Ca (Primary) ; Peginterferon alfa-2a; Thymalfasin
  • Indications Hepatitis B
  • Focus Adverse reactions; Proof of concept
  • Sponsors REPLICor
  • Most Recent Events

    • 14 Apr 2018 Results assessing mathematical model that predicts HBV DNA, HBsAg and transamin- ase kinetic parameters against HBV during REP 2139 monotherapy in the REP 102 protocol (NCT02646189) presented at The International Liver Congress 2018
    • 07 Jun 2016 Results published in the journal PLOS ONE, according to a REPLICor media release.
    • 07 Jun 2016 Results published in a REPLICor media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top